Product Name:
CDK7-pT170
Product Number:
ab-pk573
Target Full Name: Cyclin-dependent protein-serine kinase 7
Target Alias: 39 kDa protein kinase; CAK; CAK1; CDK-activating kinase; CDKN7; CR4 protein kinase; CRK4; TFIIH basal transcription factor complex kinase subunit; HCAK; MO15; STK1; CDKN7; p39MO15; Q14495; CCDS3999.1; ENSG00000134058
Product Type Specific: CDK7 protein kinase phosphosite-specific antibody
Antibody Code: PK573
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y170
Protein UniProt: P50613
Protein SigNET: CDK7
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDK7 sequence peptide Cat. No.: PE-04AJR99
Antibody Immunogen Sequence: RAY(pY)HQV(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R167 to V173I. T170 phosphorylation stimulates phosphotransferase activity and regulates transcription. This phosphosite is located in the kinase activation loop between catalytic subdomains VII and VIII. This is the major in vivo phosphorylation site in CDK7 (≥152 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). CDK7 is known to be phosphorylated at this site in vitro by CDK1 (CDC2), CDK2, and PKCi.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque | Dog | Rat | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 38-43 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in T98G cells, but a maturation-activated 75 kDa cross-reactive protein was evident in sea star oocytes.
Related Product 1: CDK7 (167-173) pT170 antibody blocking peptide (Cat. No.: PE-04AJR99)
Related Product 2: CDK7/9Subtide kinase substrate peptide (Cat. No.: PE-01BGR99)
Related Product 3: RNA polymerase II-CT KinSub - heptapeptide repeat from C-terminus peptide; CDKtide protein kinase substrate peptide
Related Product 4: CDK7 (CDK7-1) pan-specific antibody (Cat. No.: AB-NK030-1)
Scientific Background: CDK7 (CAK1) is a protein-serine/threonine kinase of the CMGC group and CDK family. It is a protein kinase that functions in cell cycle control and in the regulation of RNA-polymerase II-mediated transcription as the catalytic subunit of the CDK-activating kinase (CAK) complex. It operates as a trimeric complex consisting of CDK7, Cyclin H, and MAT1. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. CDK7 is required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 phosphorylates many proteins including SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by direct threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminus domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. CDK7 is required for DNA-bound peptides-mediated transcription and cellular growth inhibition. In the presence of DNA-damage, CDK7 phosphorylates and activates p53/TP53, which then feeds back and inactives CDK7, leading to cell cycle arrest. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis. This description may include information annotated by UniProt and/or Google AI.